Marat Fudim, MD MHS

🚨 Calling all #HeartFailure friends and colleagues Our 1⃣st Devices in Heart Failure day at @HFSA 🔬Mechanisms,💡Implementation, 🖐️Hands on 📅 Sep 26 Minneapolis Details➡️ hfsa.org/asm/hfsa-devic… Special Events:⭐️Trial Tinder and ♥️Heart Tank Apply➡️hfsa.org/sites/default/…

Absolutely tour de force @DukeHeartCenter cardiology grand rounds by the all star fellow @aarti693 on systems barriers to cardiometabolic prevention!! So excited to have her join us at Duke Heart Next year on faculty!!!

CONFIDENT-HFpEF: A Machine Learning-Based Risk Stratification for Mortality and Hospitalization Using Multimodal Real-World Data see @ESC Heart Failure ow.ly/4Seu50YGSbX #ESCHeartFailure @EJHFEiC @JanBiegus @Ppponikowski #HFA_ESC @hvanspall @ShelleyZieroth @FudimMarat @gcfmd @MarcoMetra @GianluSava

Nominations for the 2026 HFC Site-Based Research Awards are now open! Winners will recognized at AHA's 2026 Scientific Sessions. What a great way to honor the hard work of PI, CRC and sites! Submit nominations here: hfcollaboratory.com/nominations/

Physician-Directed Patient Self-Management Using an Implantable IVC Congestion Sensor: Insights from FUTURE HF II Physician-directed patient self-management using ambulatory IVC-based congestion monitoring was feasible, associated with increased signal-driven intervention, and not associated with adverse safety signals. #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @JACCJournals @ACCinTouch @FudimMarat @DrMarthaGulati @hvanspall @SJGreene_md @gcfmd @AndrewJSauer @ankeetbhatt jacc.org/doi/10.1016/j.…

Physician-Directed Patient Self-Management Using an Implantable IVC Congestion Sensor: Insights from FUTURE HF II Physician-directed patient self-management using ambulatory IVC-based congestion monitoring was feasible, associated with increased signal-driven intervention, and not associated with adverse safety signals. #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @JACCJournals @ACCinTouch @hfcollaboratory @FudimMarat @mvaduganathan @SJGreene_md @SJGreene_md @ShelleyZieroth @hvanspall sciencedirect.com/science/articl…

HFpEF now accounts for >50% of HF worldwide and is closely linked to systemic HTN. Overview of intensive BP management in HFpEF—spanning prevention, symptom relief, reverse remodeling, and emerging therapies such as renal denervation (link.springer.com/article/10.100…). #HREV @FudimMarat

New @JACCJournals #JACCHF 🫀   @ba_steinberg @FudimMarat @jlharrington_m ‼️#HFpEF across the #BMI spectrum‼️ ⬆️BMI ⭐️Larger LVEDD & LA size ⭐️Higher PA an PCWP ⭐️⬆️Risk HF hospitalization ⬇️BMI ⭐️⬆️Risk of death DOI: 10.1016/j.jchf.2025.102768

Watch Martin Leon and @FudimMarat recap the highlights from yesterday's first day of #THT2026 in Boston. tctmd.com/videos/tht-202…

Now in @JACCJournals #JACCHF What is the feasibility of physician-directed patient self management using ambulatory IVC based congestion monitoring ? Insights from the FUTURE-HFII trial Link: jacc.org/doi/10.1016/j.… SimPub @crfheart #THT2026 @FudimMarat

Last month, the first-in-human gene therapy trial for HFpEF completed enrollment, a significant milestone that DCRI’s @FudimMarat says can allow researchers “to gather the additional safety and efficacy data needed” for Phase 2b progression. Read more: citybiz.co/article/788645…

3. Unified diagnostics & therapeutic strategies targeting common metabolic pathways may improve outcomes in both conditions. We need integrated, mechanism-based care that breaks organ silos to better tackle cardiometabolic disease @gabrieleschiat1 nature.com/articles/s4156…

2.Inter-organ crosstalk: Beyond shared risk factors, liver/heart communicate via lipotoxicity, inflammation, oxidative stress, and liver-derived signals (hepatokines etc) that influence cardiac structure & function. Recognizing this crosstalk reframes HFpEF as multiorgan disease

🧵1. HFpEF (heart failure w/ preserved ejection fraction) & MASLD (metabolic dysfunction-associated steatotic liver disease) are rising together with obesity/metabolic syndrome. Once siloed, now reflect shared systemic metabolic dysfunction driving disease in both heart & liver.

Mark it down ➡️ June 6, 2026 💙 Duke Heart Failure Symposium - The South-East Meeting on ALL around the topic of Heart Function, Implementation and Innovation. World-class faculty and exhibitors are guaranteed! Registration page ⬇️ medicine.duke.edu/education-and-…

3. Beyond symptom scores, the trial integrates autonomic testing, functional capacity, QoL, and biomarker profiling, aiming to define who benefits and why This is one of the most ambitious LongCOVID/POTS trials to date Stay tuned for part 1 @ #ACC26 in New Orleans. @PamTaubMD

2. Why this matters: Millions w/ LongCOVID suffer from orthostatic intolerance, tachycardia, fatigue, and impaired quality of life with no proven therapies RECOVER-Autonomic is testing: • IVIG • Ivabradine • Coordinated non-pharma care Rigorous. Scalable. Mechanistic.

🧵1. Big news in #LongCOVID research. The methods paper for the RECOVER-Autonomic Trial is now published — and the trial will be presented at #ACC26 in New Orleans This NIH platform study is designed to test targeted therapies for LongCOVID POTS sciencedirect.com/science/articl…

Check out this report on how upright testing can highlight preload limitations not seen while supine during RHC @vkittipibul @FudimMarat ahajrnls.org/4as5hee

@AndrewJSauer I am already prepping the table and metabolic cart.

Is it bad that I imagine right heart cath with exercise hemodynamics on this guy, just because I’m completely fascinated by why his numbers would look like? Mind blowing.

In our @NatureMedicine pub we argue that the central challenge of clinical AI isn't model performance, but context. We propose a new role for physicians as context engineers who govern how AI reasons, not just what it predicts. @FudimMarat @JonPicciniSr @ZakLoringMD @venkmurthy